InnoCare Pharma Reports 88% Revenue Growth and RMB 648.3M Profit
Revenue for the first three quarters of 2026 rose 88% year over year to RMB 2.1 billion. Net profit was RMB 648.3 million, versus a RMB 72.0 million loss a year earlier; drug sales rose 41.5% to RMB 1.4 billion.
InnoCare Pharma posted RMB 2.1B revenue for the first three quarters of 2026, up 88% YoY, and net profit of RMB 648.3M versus a RMB 72.0M loss a year ago. Drug sales rose 41.5% YoY to RMB 1.4B.Material DetailsContext by AI AnalystThis confirms a profitability turn with accelerating revenue, bolster…